Recursion Pharmaceuticals (RXRX)
Builds investigational medicines through automated biology, AI chemistry, and partner programs.
$4.02
After hours−0.03 (−0.74%)
At close$4.05(+2.02%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 68.38% | 366.07M shares | |
|---|---|---|---|
| 361 holders · as of Jun 30, 2026 | |||
| Insiders | 3.65% | 19.56M shares | |
| 13 holders · as of Sep 16, 2026 | |||
| Other | 27.97% | 149.71M shares | |
| remainder | |||
535.34M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
361 holders · 366.07M shares · 55 new positions · 184 increased · 103 reduced · 44 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 50.30M | 9.40% | +7.11M | Aug 7, 2026 |
| Ark Investment Management LLC | 41.34M | 7.72% | +1.12M | Aug 14, 2026 |
| State Street Corp | 34.71M | 6.48% | +6.22M | Aug 7, 2026 |
| Vanguard Portfolio Management LLC | 31.13M | 5.82% | +8.37M | Aug 13, 2026 |
| Baillie Gifford & Co | 23.49M | 4.39% | −187.5K | Aug 6, 2026 |
| Vanguard Capital Management LLC | 22.77M | 4.25% | +521.6K | Aug 13, 2026 |
| Geode Capital Management, LLC | 13.82M | 2.58% | +1.54M | Aug 12, 2026 |
| SoftBank Group Corp. | 13.64M | 2.55% | 0 | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| ARK Investment Management LLC | 7.25% | 37.32M | 13G | Feb 3, 2026 |
| BlackRock, Inc. | 7.20% | 37.82M | 13G | Apr 24, 2026 |
| State Street Corporation | 6.60% | 34.71M | 13G | Aug 7, 2026 |
| Baillie Gifford & Co | 6.50% | 24.86M | 13G | Feb 12, 2025 |
| Vanguard Portfolio Management | 5.97% | 31.37M | 13G | Jul 31, 2026 |
| Vanguard Capital Management | 5.09% | 26.74M | 13G | Jul 31, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 8, 2026 | Najat Khandirector, officer: CEO and President | Sale | 22,408 | $3.52 | 2,072,890 |
| Sep 1, 2026 | Blake Borgesondirector | Sale | 30,000 | $3.34 | 6,158,287 |
| Aug 4, 2026 | Blake Borgesondirector | Sale | 30,000 | $3.25 | 6,188,287 |
| Jul 7, 2026 | Blake Borgesondirector | Sale | 40,000 | $3.96 | 6,218,287 |
| Jun 18, 2026 | Namandje Bumpusdirector | Sale | 3,963 | $3.18 | 127,632 |
| Jun 5, 2026 | Najat Khandirector, officer: CEO and President | Sale | 23,588 | $3.58 | 2,175,796 |
| Jun 5, 2026 | Christopher Gibsondirector | Sale | 40,000 | $3.62 | 883,735 |
| Jun 2, 2026 | Blake Borgesondirector | Sale | 30,000 | $3.68 | 6,169,863 |
| Jun 3, 2026 | Namandje Bumpusdirector | Sale | 4,386 | $3.54 | 43,171 |
| May 22, 2026 | Christopher Gibsondirector | Sale | 40,000 | $3.08 | 883,735 |
House and Senate disclosures
Not reported.